Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride

1. The compound N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride in crystalline form, made by a process comprising the steps of:

a) adding N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide and methyl t-butyl ether to form a mixture;

b) adding HCl acid to the mixture and stir at above room temperature;

c) allowing the mixture to return to room temperature; and

d) isolate and dry the prepared compound.

2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

3. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier and an effective amount of a compound of claim 1 , which process comprises bringing the compound of claim 1 into association with a pharmaceutically acceptable carrier.

4. A method of inhibiting Akt activity in a mammal, which comprises administering to such mammal an inhibitory amount of a compound of claim 1 .

5. The method of claim 4 wherein the mammal is a human.

6. Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride having characteristic diffraction peaks at 14.4°±0.3° and 32.4°±0.3° in an Powder X-Ray Diffractogram using Cu Kα radiation.

7. Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride having the characteristic diffraction peaks recited in claim 6 and having characteristic diffraction peaks at 25.1°±0.3° and 25.7°±0.3° in the Powder X-Ray Diffractogram using Cu Kα radiation.

8. Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride having the characteristic diffraction peaks recited in claim 7 and having characteristic diffraction peaks at 21.5°±0.3° and 20.8°±0.3° in the Powder X-Ray Diffractogram using Cu Kα radiation.

9. A pharmaceutical composition comprising the compound of claim 6 and a pharmaceutically acceptable carrier or diluent.

10. A method of inhibiting Akt activity in a mammal, which comprises administering to such mammal an inhibitory amount of a compound of claim 6 .

11. The method of claim 10 wherein the mammal is a human.